{
  "ticker": "TGTX",
  "company_name": "TG Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02013128",
      "title": "Ublituximab + Ibrutinib in Select B-cell Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma",
      "start_date": "2014-01-06",
      "completion_date": "2015-12",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07103746",
      "title": "Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "condition": "Autoimmune Disorders",
      "start_date": "2026-01",
      "completion_date": "2030-06",
      "enrollment": 0,
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)"
    },
    {
      "nct_id": "NCT03379051",
      "title": "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma",
      "start_date": "2018-03-27",
      "completion_date": "2022-06-16",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02268851",
      "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma",
      "start_date": "2014-11",
      "completion_date": "2022-10",
      "enrollment": 0,
      "sponsor": "Dana-Farber Cancer Institute"
    },
    {
      "nct_id": "NCT02738775",
      "title": "Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Multiple Sclerosis",
      "start_date": "2016-05-27",
      "completion_date": "2018-08-13",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07220252",
      "title": "Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Relapsing Multiple Sclerosis",
      "start_date": "2025-12-01",
      "completion_date": "2033-06-30",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT01744912",
      "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia",
      "start_date": "2012-11-21",
      "completion_date": "2014-02-07",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02100852",
      "title": "TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Chronic Lymphocytic Leukemia",
      "start_date": "2014-03-12",
      "completion_date": "2017-11",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03804996",
      "title": "Study of TG-1801 in Subjects With B-Cell Lymphoma",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "B-Cell Lymphoma",
      "start_date": "2019-03-05",
      "completion_date": "2024-02-21",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03207256",
      "title": "Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma",
      "start_date": "2017-08-09",
      "completion_date": "2022-06-24",
      "enrollment": 0,
      "sponsor": "TG Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 45,
    "by_phase": {
      "PHASE1, PHASE2": 3,
      "PHASE2": 14,
      "PHASE1": 13,
      "PHASE2, PHASE3": 3,
      "PHASE3": 7,
      "PHASE4": 1,
      "": 3,
      "NA": 1
    },
    "by_status": {
      "COMPLETED": 16,
      "NOT_YET_RECRUITING": 3,
      "TERMINATED": 17,
      "RECRUITING": 7,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 9,
    "completed_trials": 16,
    "conditions": [
      "Autoimmune Disorders",
      "B-Cell Lymphoma",
      "B-cell Mediated Autoimmune Disorders",
      "B-cell Non Hodgkin Lymphoma, Richter's Transformation",
      "CLL, SLL, Richter's Transformation, Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Aggressive Lymphoma, DLBCL, Mediastinal Large B-cell Lymphoma, MCL",
      "Chronic Lymphocytic Leukemia",
      "Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL",
      "Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma",
      "Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma",
      "Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma",
      "Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma",
      "Chronic Lymphocytic Leukemia, Richter Syndrome",
      "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",
      "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia",
      "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma",
      "Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma",
      "Follicular Lymphoma",
      "Follicular Lymphoma, Small Lymphocytic Lymphoma",
      "Hodgkin's Lymphoma",
      "Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma",
      "Multiple Sclerosis",
      "Multiple Sclerosis (MS) - Relapsing-remitting",
      "Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting",
      "Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia",
      "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma",
      "Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma",
      "Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia",
      "Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST)",
      "Relapsing Multiple Sclerosis",
      "Relapsing Multiple Sclerosis (RMS)",
      "Relapsing Multiple Sclerosis, Multiple Sclerosis",
      "Relapsing Remitting Multiple Sclerosis"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:45:01.366940",
    "search_query": "TG Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=TG+Therapeutics,+Inc."
  }
}